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ABSTRACT
Background: Cerebral Amyloid Angiopathy has been indicated as an important 
cause of spontaneous non-hypertensive intracerebral haemorrhage (ICH).
Aims: to analyze the presence of β-amyloid deposit in the temporal artery of 
consecutive patients with ICH in comparison to control subjects and its relation to 
APO-E haplotype frequency. 
Methods: We enrolled consecutive patients admitted to Neurosurgery Ward of 
University Hospital “P. Giaccone” of Palermo with a diagnosis of spontaneous non 
hypertensive ICH and as control 12 subjects without brain haemorrhage. Biopsy 
of superficial temporal artery has been performed and β-amyloid deposit was 
quantified. 
Results: Among 25 subjects with ICH, 10 (40%) had APOE epsilon 2 allele and 
among these subjects 7 (70%) showed amyloid accumulation on temporal artery 
specimens, 8 (32%) subjects had APOE epsilon 3 allele and among these subjects 
only 2 (25%) showed amyloid accumulation on temporal artery specimens, whereas  
7 (28%) had APOE epsilon 4 allele and of these, 7 (100%) showed amyloid 
accumulation on temporal artery specimens. At multivariable logistic regression 
analysis for the presence of amyloid, predictive factors for the presence of amyloid 
in temporal artery biopsies were: age, hypertension, intralobar site of haemorrhage, 
APOE epsilon 2 and APOE epsilon 4 alleles. 
Discussion: Our findings of a higher frequency of amyloid deposition in temporal 
artery specimens in subjects with spontaneous intracerebral haemorrhage indicate 
a possible role of temporal artery as a possible diagnostic site of biopsy in subjects 
at high risk to develop intracranial haemorrhage related to Cerebral Amyloid 
Angiopathy.
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INTRODUCTION
Spontaneous non-traumatic intracerebral 
haemorrhage (ICH) is the second most prevalent 
subtype of stroke, and it has been associated with high 
mortality and morbidity throughout the world [1, 2]. It 
usually results from the rupture of small arteries in the 
brain and represents 10–30% of all strokes [3]. In recent 
years, Cerebral Amyloid Angiopathy (CAA) has been 
rediscovered as a common cause of spontaneous ICH 
[4, 5]. CAA refers to the deposition of β-amyloid (Aβ) in 
the media and adventitia of small and mid-sized arteries of 
the cerebral cortex and the leptomeninges [4].
Some authors described the pathological features 
associated with CAA: -preferential involvement of the 
small arteries and capillaries of the meninges, cerebral 
cortex, and cerebellar cortex [6]; -a topographical 
distribution favouring the posterior brain regions, most 
frequently involving the occipital lobes [7]; -lack of 
staining of vessels in the white matter [8]; -association 
with increased age and the presence of dementia [9]; -lack 
of association with hypertension and arteriosclerosis [10]; 
-lack of association with amyloidosis of the other organs 
[11, 12]. 
Pathologically defined CAA is common in the 
elderly. Population based autopsy studies indicate a CAA 
prevalence of 20–40% in non-demented and 50–60% in 
demented elderly populations [13–17]. Advancing age 
is the strongest known clinical risk factor for developing 
CAA [13–15, 18–22, 25].
In contrast with hypertensive arteriopathy, the other 
form of small vessel disease and cause of ICH, the risk of 
CAA is not accounted for by conventional cardiovascular 
risk factors other than age [23]. Hypertension is not 
considered a risk factor for developing CAA but it may 
increase the risk of CAA related ICH [23]. 
The temporal artery is a blood vessel in the scalp 
on the side of the head and superficial temporal artery is a 
major artery of the head. It arises from the external carotid 
artery when it bifurcates into the superficial temporal 
artery and maxillary artery. Temporal artery biopsy (TAB) 
is a procedure that involves removing a small section of 
the temporal artery and it has previously been considered 
fundamental to making the diagnosis in clinical setting 
of giant cell arteritis (GCA). Few studies analyzed the 
potential role of TAB in other diseses such as those 
with pathological accumulation on brain vessels such as 
CAA. A single study reported a case of amyloidosis AL 
associated with light lambda chain myeloma, mimicking 
giant cell temporal arteritis [24].
No study has evaluated the presence of β-amyloid 
deposits in the temporal artery in subjects with 
intracerebral haemorrhage. The demonstration of 
β-amyloid accumulation in bioptic specimens from 
temporal artery may represent a useful clinical opportunity 
since the easier surgical access also in vivo to this 
arterial site. 
Our study hypothesis was that in subjects with 
non-hypertensive brain haemorrhage the histological 
analysis of specimens obtained by TAB could offer 
useful diagnostic information towards a possible ex-vivo 
diagnosis of CAA based on the presence of β-amyloid 
accumulation on the wall of superficial temporal artery.
Thus, we designed a case control study with these 
aims: -to evaluate the presence of β-amyloid deposit in 
temporal artery specimens of consecutive patients with 
spontaneous non-hypertensive intracerebral haemorrhage 
in comparison to control subjects; -to assess the frequency 
of the APO-E alleles in subjects with spontaneous non-
hypertensive intracerebral haemorrhage with regard to 
β-amyloid accumulation in temporal artery specimens; 
-to analyse the predictive role of clinical, laboratory and 
genetic variables towards the presence of β-amyloid 
accumulation in temporal artery biopsies.
RESULTS
We enrolled 25 consecutive subjects with 
spontaneous intracerebral haemorrhage. 
General and clinical characteristics of patients with 
spontaneous intracerebral haemorrhage were listed in 
Table 1. Mean age was 66 ± 5.19 years. 16 were males 
and 9 were females,14 (56%) had hypertension, 5 (20%) 
had diabetes, 8 (32%) had dyslipidemia, 4 (16%) had a 
previous stroke, 5 (20%) had a previous smoking habit. 
With regard to ICH localization, 18 (72%) had 
a lobar intracerebral haemorrhage and 7 (28%) had a 
non-lobar intracerebral haemorrhage (4 ganglionic and 
3 brainstem/ cerebellum).
We observed a β-amyloid deposit in 19 subjects with 
ICH and in 3 control subjects (see Table 1).
Subjects with ICH in comparison with controls 
showed a higher severity of amyloid accumulation either 
according the Vonsattel scale (2.6 ± 0.9 vs 1.1 ± 0.8) and 
a higher percentage of β-amyloid deposit measured by 
Mountjoy scale (3.56 ± 1.1 vs 1.38 ± 0.7) (see Tables 1 
and 2 and Figures 1–2).
Apolipoprotein E allele frequencies in subjects with 
ICH were: 10 (40%) had APOE epsilon 2 allele and among 
these subjects 7 (70%) showed β-amyloid accumulation 
on temporal artery specimens, 8 (32%) had APOE epsilon 
3 allele and among these subjects only 2 (25%) showed 
β-amyloid accumulation on temporal artery specimens, 
7 (28%) had APOE epsilon 4 allele and of these 100 (%) 
showed β-amyloid accumulation on temporal artery 
specimens. 
Among subjects without spontaneous intracerebral 
haemorrhage only 3 subjects showed β-amyloid 
accumulation on temporal artery specimens and all these 
subjects had APOE epsilon 3 allele (see Table 1). 
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At multivariable logistic regression analysis for 
presence of β-amyloid in temporal artery specimens of 
patients with spontaneous ICH, predictive variables for 
the presence of β-amyloid in temporal artery biopsies 
were: age (per 1 year) (OR: 1.48; p = 0.035), hypertension 
(OR: 2.23; p = 0.085), intralobar site of haemorrhage 
(OR: 1.66; p = 0.03), APOE epsilon 2 allele (OR: 1.96; 
p < 0.0001), APOE epsilon 4 allele (OR: 1.88; p < 0.0001) 
(see Table 3).
DISCUSSION
We report that in subjects with spontaneous 
intracerebral haemorrhage, histological analysis of 
temporal artery specimens show an accumulation of 
β-amyloid. In subjects with intracerebral haemorrhage 
in comparison with controls we also observed a higher 
severity of amyloid accumulation either according the 
Vonsattel and the Mountjoy scales.
To our best knowledge, there are no reports 
concerning the temporal artery involvement in CAA 
or ICH. Therefore, we tried to find out how often 
the temporal artery are deposited by β-amyloid in 
subjects with ICH due to non-hypertensive spontaneous 
intracerebral haemorrhage. We report that this arterial 
site is more likely to be interested by β-amyloid deposit 
in subjects with ICH in comparison with control subjects. 
 Furthermore, concerning APO-E aplotype we tried 
to speculate if β-amyloid accumulation could be related to 
the presence of CAA.
Neuropathological examination is still a “gold 
standard” for CAA diagnosis but no study, to the best 
of our knowledge, examined the role of temporal artery 
biopsy in the diagnosis of β-amyloid accumulation and 
Table 1: Baseline characteristics in patients with intracerebral spontaneous haemorrhage and in control subjects 
Patients with intracerebral 
haemorrhages (n: 25) 
Control subjects (n: 12) 
Age 66 ± 5.19 67 ± 6.06
Sex (M/F) (n%) 16/9 (64/36) 7/5 (58.3/42.7)
Hypertension (n%) 14 (56) 7 (58.33) 
Diabete (n%) 5 (20) 4 (33.3)
Dyslipidemia 8 (32) 4 (33.3)
Previous stroke 4 (16) 2 (16.6)
Smoking current 5 (20) 2 (16.6) 
Smoking previous 4 (16) 2 (16.6) 
Serum glucose (mg/dL) 128.1 ± 23.1 121.1 ± 14.3
Total cholesterol (mg/dL) 189.5 ± 37.4 179.5 ± 41.4
HDL cholesterol (mg/dL) 57.0 ± 18.6 49.0 ± 18.6
LDL cholesterol (mg/dL) 101.7 ± 13.4 109.5 ± 21.7
Triglyceride (mg/dL) 122.8 ± 51.5 131.4 ± 37.1
Serum creatinine (mg/dL) 0.95 ± 0.18 0.89 ± 0.31
eGFR (mL/min/1.73 m2) 88.4 ± 22.5 89.8 ± 13.2
Location of ICH (n%)
- Ganglionic
- Lobar
- brainstem/cerebellum
4 (16)
18 (72)
3 (12)
−
−
−
Amyloid accumulation 19 (76) 3 (25)
CAA severity according the 
Vonsattel scale 
(mean ± ds) 
2.6 ± 0.9 1.1 ± 0.8
CAA severity according the 
Mountjoy scale (mean ± ds)
3.56 ± 1.1 1.38 ± 0.7
Apo-E alleles (n%)
-epsilon 2 allele 
-epsilon 3 allele
-epsilon 4 allele
10 (40%)
8 (32%)
7 (28%)
−
3 (25)
−
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its practical application to perform diagnosis of CAA 
in subjects with organ complications such as cerebral 
amyloid angiopathy haemorrhage (CAAH).
Cerebral amyloid angiopathy is characterised by 
deposition of amyloid β-protein (Aβ) within the walls of 
medium and small-sized arteries in the cerebral cortex 
Table 2: Cerebral amyloid angiopathy severity in temporal arterie of patients with intracerebral haemorrhages 
Number/initials age sex CAA severity according the 
Vonsattel scale 
CAA severity according the 
Mountjoi scale
1 67 M 1 3
2 71 M 3 4
66 F 3 4
4 68 M 3 4
5 59 F 3 4
7 68 F 3 4
8 70 3 4
9 65 M 3 4
10 68 M 3 4
11 73 F 3 4
12 57 F 3 3
13 61 F 3 3
14 59 M 2 4
15 66 M 3 3
16 65 M 3 4
17 63 F 3 4
18 62 F 3 4
19 59 F 2 4
20 57 M 3 4
21 77 M 3 4
22 81 M 1 3
23 64 F 3 3
24 62 M 3 3
25 69 M 3 4
Figure 1: Superficial temporal artery specimen from a 67 year old male patient with spontaneous intracerebral 
haemorrhage and apo ε2 genotype. (A) Congophilic amorphous material in the muscular wall of the superficial temporal artery. (B) 
The polarized light evidences a linear “apple green” birefringence, related to amyloid deposites. (Congo Red, 100x).
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and leptomeninges [1]. These pathological changes lead 
to increased vascular fragility and predisposes to rupture 
of the blood vessel. 
Our finding of a higher rate of amyloid accumulation 
in temporal artery specimens could offer a new diagnostic 
tool for CAA and a possible method to stratify population 
at risk of CAAH. Our results seem to sustain the role of a 
possible diagnosis of CAA based on histological analysis 
of temporal artery specimen. Thus, it could be possible 
to hypothesize an underestimation of CAA owing to the 
low percentage of patients that underwent post-mortem to 
pathological and histological screening for CAA and that 
an extended use of TAB could show an increased CAA 
prevalence. 
Vinters [25] in a clinico-pathological series of 107 
pathologically proven CAA cases found the prevalence 
of hypertension to be around 32%, similar to community-
dwelling elderly populations, while another pathological 
study [26] reported that CAA patients with ICH were 
more frequently hypertensive (50%) than those without 
ICH (23%), suggesting that hypertension may contribute 
to CAA related cerebral bleeding. 
In a recent multicentre cohort of patients with 
spontaneous ICH, some authors found that the prevalence 
of hypertension in CAA related ICH was 62% significantly 
less than in non-CAA related ICH (85%) [27–30].
Individuals carrying the Apo-epsilon 2 allele also 
have an increased risk of CAA related lobar ICH [38]. 
Both of these risk alleles have been also reported as 
associated with a younger age of first ICH, [39] greater 
likelihood of hematoma expansion, poorer clinical 
outcome [30–38] and a higher risk of recurrence [39]. 
Patients with both Apo epsilon 2 and 4 alleles have the 
earliest disease onset and high risk of early ICH recurrence 
[40–42]. 
The evidence available to date concerning a possible 
association between apoE genotype and haemorrhage due 
to CAA (CAAH) are not univocal. Some studies reported 
a high APOE epsilon 4 allele frequency in such patients 
[43–45] whereas others a high frequency of APOE epsilon 
2 allele [46, 47]. More than 40% of patients with CAA-
related haemorrhage have associated AD [48, 49], which 
may confound the analysis because APOE epsilon 4 allele 
is a well-established risk factor for AD [50–53], whereas 
APOE epsilon 2 allele is protective [54, 55].
It has been reported by some authors that CAA-
associated vasculopathic complications precede vessel 
rupture and cerebral haemorrhage [56–58].
Two studies have reported that the APOE epsilon 
2 allele allele is associated with some of these vascular 
complications. Among 75 brains with CAA, Greenberg 
et al. [59, 60] found an elevated APOE epsilon 2 allele 
frequency in brains that demonstrated both vessel 
wall cracking and evidence of paravascular blood 
leak compared to brains without this combination of 
vasculopathies.
Another study recently analyzed CAA-associated 
vasculopathic complications among CAA patients with 
and without macroscopic evidence of lobar haemorrhage 
[61]. The authors reported that stenosed blood vessels, 
dilated/microaneurysmal vessels and fibrinoid 
necrosis were more common in patients with CAAH 
than in patients with CAA but without macroscopic 
lobar haemorrhage. Thus, authors suggested that this 
structural change in the vessel wall may represent the 
pathogenetic link between APOE epsilon 2 allele and 
CAAH [61–63].
Our findings of a higher frequency of β-amyloid 
deposition in temporal artery specimens in subjecs with 
spontaneous intracerebral haemorrhage indicate a possible 
Figure 2: Superficial temporal artery specimen from a 68 year old female patient with spontaneous intracerebral 
haemorrhage and apo ε4 genotype. (A) Congophilic amorphous material in the muscular wall of the superficial temporal artery. (B) 
The polarized light evidences week granular “apple green” birefringence, related to amyloid deposites. (A, B: Congo Red, stain 200x).
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role of temporal artery as a marker arterial site of CAA in 
subjects at high risk to develop CAAH. 
Furthermore our finding of a higher prevalence 
of APOE epsilon 2 allele and APOE epsilon 4 allele in 
subjects with spontaneous intracerebral haemorrhage 
and β-amyloid accumulation on temporal artery biopsy 
specimen could suggest that temporal artery should 
be considered as a possible arterial site of amyloid 
accumulation thus to represent a candidate diagnostic 
marker of CAA in subjects with predisposing APOE 
genotypes. Furthermore, future studies addressing analysis 
β-amyloid accumulation on temporal artery specimens 
could also offer interesting perspectives about the risk of 
rebleeding in subjects with ICH.
Limitations 
We have not performed standard histological 
diagnosis of CAA on the basis of the post-mortem 
histological findings that permit to distinct two types of 
CAA: CAA type 1, characterised by β-amyloid in cortical 
capillaries (with or without involvement of other vessels) 
and CAA type 2, where β-amyloid deposits are restricted 
to leptomeningeal and cortical arteries, arteriolesand, 
rarely, veins [2, 3]. 
METHODS
We enrolled all consecutive patients admitted to 
Neurosurgery Ward of University Hospital “P. Giaccone” 
of Palermo with a diagnosis of spontaneous non-
hypertensive ICH from December 2014 to January 2016.
The diagnosis of non-hypertensive intracerebral 
haemorrhage was based on these criteria [64]: -lobar 
anatomic location; -extra-pontine anatomic location 
(ganglionic, thalamic or cerebellar); -no diagnostic 
evidence of small vascular malformations (intracerebral 
arteriovenous malformations, cavernous angiomas, or 
venous angioma); -no diagnostic evidence of brain tumors; 
-no history of a previous treatment with pro-haemorragic 
drugs such as anticoagulants, amphetamines and other 
sympathomimetic drug.
Control subjects comprised 12 histologically normal 
temporal artery samples from 12 consecutive patients 
(7 women, 5 men; median 74 years, range: 60–84 years) 
enrolled in a previous study [65] that recruited patients 
with suspected giant cell arteritis but with negative biopsy 
results. 
Control patients had no clinical history of 
cerebrovascular accidents (TIA, ischemic stroke and ICH) 
or Alzheimer Disease (AD). 
The diagnosis in control patients was: fever of 
unknown origin (five patients), isolated polymyalgia 
rheumatica (five patients), non-specific headache in the 
presence of osteoarthritis (five patients). 
This study has been approved by the Ethics 
Committee of the University of Palermo. Signed informed 
consent for the collection and storage of biological 
material has been also obtained from all the patients 
enrolled in this study. All patients gave their informed 
consent before enrolment into the study.
Temporal biopsy
Biopsy of superficial temporal artery was performed 
by a specialist neurosurgeon under local anesthesia if there 
are no contraindications. The superficial temporal arteries 
were palpated bilaterally and if the vessel is not easily 
palpable, hand-held Doppler can be used to localize it. 
Once the artery is identified, the surgical site is marked. 
Intraoperative view of excised temporal artery. A specimen 
of at least 2 cm in vivo has been harvested.
Table 3: Multivariable logistic regression analysis for presence of amyloid in temporal artery specimens of patients 
with spontaneous intracerebral haemorrhage 
OR 95% CI p-value
Age (per 1 year) 1.48 1.01–1.99 0.035
Hypertension 2.23 0.83–5.05 0.085
diabetes 2.09 1.12–8.56 0.03
Smoking 1.03 0.51–5.42 0.408
eGFR 0.99 0.98–1.01 0.689
Intralobar 1.66 0.61–4.56 0.03
Prior stroke 0.67 0.61–2.34 0.120
Dyslipidemia 0.74 0.55–1.76 0.609
Total cholesterol 0.56 0.48–2.11 0.709
Triglyceride 0.88 0.58–1.97 0.505
APOE epsilon 2 allele 1.96 1.11–2.52  < 0.0001
APOE epsilon 4 allele 1.88 1.10–2.35  < 0.0001
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Histological evaluation
Biopsy specimens were evaluated by two 
experienced pathologists who had no access to clinical 
data. Artery biopsy specimens showed a range in length 
from 0.5 cm to 3.1 cm.
Amyloid deposits were detected by Congo Red 
staining. Congo Red staining can then be viewed under 
plane-polarized light. Amyloid plaques should give apple-
green birefringence, usually as a Maltese cross.
The specimens were stained with H&E, PAS, Congo 
red and immunohistochemically with two antibodies: anti 
Aβ 8 17 (DAKO, 1: 50), actin (SMA, DAKO, 1: 50). Under 
microscopic evaluation the temporal artery specimen was 
considered positive for CAA when it showed at a yellow-
green birefringence under polarized light.
After histological review, biopsy specimens were 
classified into one of the following three categories: 1) 
β-amyloid presence; 2) no β-amyloid amyloid presence; 3) 
atherosclerotic disease.
To quantify β-amyloid we used Vonsattel method. 
Vonsattel et al. [23] graded CAA with regard to the 
severity of pathological changes in a given blood vessel: 
1-mild, β-amyloid is restricted to the tunica media 
without significant destruction of smooth muscle cells; 
2- moderate, the tunica media is replaced by β-amyloid 
and is thicker than normal; 3-severe, extensive β-amyloid 
deposition with focal wall fragmentation or even double 
barrelling of the vessel wall, microaneurysm formation, 
fibrinoid necrosis, and leakage of blood through the blood 
vessel wall.
The estimated proportion of β-amyloid deposit 
involvement in each blood vessel was recorded on the 
Mountjoy scale from 0 to 4. A score of 0 indicated the 
absence of β-amyloid. The finding of β-amyloid deposits of 
up to one-quarter of the vessel circumference was score 1. 
A score 2 marked β-amyloid deposits in up to one-half of 
the vessel circumference. The involvement of β-amyloid 
of up to three-quarters of the vessel circumference was 
score 3. Finally, score 4 indicated the total involvement of 
the vessel circumference [24].
Apolipoprotein E genotyping 
ApoE genotyping was performed, blind to the 
histological assessments, using a hot start polymerase 
chain reaction (PCR) method that had been optimized for 
archival formalin-fixed- paraffin-embedded tissue [66].
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